What is Halozyme?
Halozyme Inc. is a prominent American biotechnology and biopharmaceutical company headquartered in San Diego, California. The firm specializes in the development and commercialization of advanced drug delivery technologies, particularly enzyme-based solutions designed to enhance the administration of biologic medicines. Halozyme's proprietary technologies facilitate subcutaneous drug delivery for therapies that traditionally require intravenous infusion, thereby improving patient convenience and treatment accessibility. Through a combination of internal therapeutic development and extensive licensing agreements with major pharmaceutical partners, Halozyme has established a robust business model generating revenue from royalties, collaborations, and commercialized products. This strategic approach has positioned the company as a key player in the global biotechnology ecosystem, enabling the expansion of its technologies' clinical and commercial reach.
How much funding has Halozyme raised?
Halozyme has raised a total of $1.1B across 10 funding rounds:
Corporate Investment
$5.5M
Stock Offering
$38.2M
Stock Offering
$60M
Stock Offering
$81.8M
Debt
$50M
Stock Offering
$107.8M
Debt
$150M
Stock Offering
$135M
Debt
$400M
Corporate Investment (2009): $5.5M led by Baxter Healthcare Corporation
Stock Issuance/Offering (2009): $38.2M supported by Undisclosed
Stock Issuance/Offering (2010): $60M featuring Undisclosed
Stock Issuance/Offering (2012): $81.8M backed by Undisclosed
Debt (2014): $50M with participation from Oxford Finance and Silicon Valley Bank
Stock Issuance/Offering (2014): $107.8M led by Undisclosed
Debt (2016): $150M supported by Pharmakon Advisors and Athyrium Capital Management
Stock Issuance/Offering (2017): $135M featuring Undisclosed
Debt (2019): $400M backed by Undisclosed
Key Investors in Halozyme
Baxter Healthcare Corporation
Baxter Healthcare Corporation is a global medical products company that provides a range of products for home, hospital, physician, and kidney care. Its involvement suggests a strategic interest in drug delivery technologies that could complement its existing healthcare solutions.
Athyrium Capital Management
Athyrium Capital Management is a leading investment management platform focused on structured investments in the global healthcare sector, investing in a diverse array of financial instruments including royalties, structured credit, and equities.
Oxford Finance
Oxford Finance is a specialty finance firm that offers flexible financial solutions to healthcare and life sciences companies worldwide, indicating a focus on supporting growth and innovation within the sector.
What's next for Halozyme?
With the recent infusion of $400M as part of its $1.1B in total capital, Halozyme is poised for accelerated expansion and further innovation. The company's focus on enhancing drug delivery systems for complex biologics aligns with the growing demand for more efficient and patient-friendly therapeutic options. Future strategic initiatives are likely to involve deepening existing pharmaceutical partnerships, exploring new applications for its proprietary enzyme technologies, and potentially expanding its internal pipeline of drug candidates. Continued investment in research and development will be crucial for maintaining its competitive edge and capitalizing on emerging opportunities in the biopharmaceutical market, particularly in areas requiring advanced drug formulation and delivery.
See full Halozyme company page
